Honor: FGFR4 Inhibitor Infigratinib Obtains FDA Fast Track Qualification for Treatment of HCC Patients

In an announcement on the Hong Kong Stock Exchange, Hermed Pharmaceutical's subsidiary announced that the U.S. Food and Drug Administration has granted fast track designation to Hermed Pharmaceutical's independently developed highly selective small molecule FGFR4 inhibitor, ipatigotine, for the treatment of liver cancer patients who have previously received immune checkpoint inhibitors and multi-targeted kinase inhibitors and have overexpression of FGF19.